Evotec Investor Day Presentation Deck

evotec PAGE 30 Pre-clinical development Strong neutralising activity in mice and non human primates • Data suggest long half-life CHIKV Genomes/ml of Plasma 109 108 107 106 105 104 103 10² 0 T 1 Strong data in various in vivo models lead to Phase I EVT894: FIH study at Duke University initiated November 2020¹) T Control - 12.5 mg/kg SAR440894 - 0.5 mg/kg SAR440894 - 2.5 mg/kg SAR440894 - 12.5 mg/kg 2 3 4 5 Days Post Infection 1 Phase I FIH study Single ascending IV doses of EVT894 (0.3, 1, 3, 10, 20 mg/kg) • 8 subjects (6 active, 2 placebo) per cohort Projected duration 14 months, started Nov 2020 Very good synergy with Just - Evotec Biologics Reference case for "Pandemic preparedness" Phase I initiated NIH 1) www.clinicaltrials.gov: NCT04441905; Sponsor: NIH Site: Duke Clinical Research Center

View entire presentation